Biosearch and IMDx Finalize cGMP Oligo Supply and Licensing Agreements for IVD Products
News Mar 16, 2011
Biosearch Technologies, Inc. (Biosearch), and IMDx (privately held), a developer and manufacturer of molecular tests, have announced that Biosearch has licensed access to the BHQ®, CAL Fluor® and Quasar® patents to IMDx. In addition, Biosearch will manufacture cGMP oligonucleotides for IMDx for use in human in-vitro diagnostics.
“Biosearch Technologies is honored to have been chosen as IMDx’s cGMP oligo provider,” says Marc Beal, Director of Corporate Development at Biosearch Technologies. “IMDx assays, powered by BHQ probing technologies, provide a potent combination for future diagnostic tests.”
“We are very pleased to be working with Biosearch. We believe BHQ probes are very effective, leading to highly differentiated products for many markets,” says Alice Jacobs, MD, Chairman & CEO of IMDx.
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019